Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Jul 3, 2025
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how pregnant patients who had severe lung problems caused by COVID-19 and needed care in the intensive care unit (ICU) recover afterward, compared to non-pregnant patients with similar conditions. The researchers want to learn more about what happens to these patients after they leave the ICU, especially focusing on ongoing health issues they might face, known as Post-Intensive Care Syndrome (PICS). They will look at medical data from about 40 patients treated between March 2020 and May 2024 to understand their recovery and how well treatments work over time.
People eligible for this study are adults (18 years or older) who were admitted to an ICU at a specific hospital with COVID-19 and lung failure, and who have since been seen in a special outpatient clinic that helps patients recovering from ICU stays. Only female patients with COVID-19-related lung failure are included. Participants can expect their health information to be reviewed to track their recovery progress and treatment outcomes. This study is not yet recruiting, but it aims to provide valuable insights into the recovery process for pregnant women and others who experienced severe COVID-19-related lung problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 18 years and older
- • Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024.
- • COVID-19 infection in temporal connection with the intensive care unit admission.
- • Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment.
- Exclusion Criteria:
- • Gender: Male
- • Diagnosis: Non-COVID or no respiratory failure
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Claudia Spies, MD, Prof.
Study Director
Charite University, Berlin, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported